Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer

Overview of attention for article published in Investigational New Drugs, October 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (73rd percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

So far, Altmetric has seen 10 X posts from 7 X users, with an upper bound of 13,294 followers.

RT @pharma_jonpi: Zepsyre ... Otras Dos Expectativa Más . "" Es Altamente Efectivo en el Cáncer Cervical Uterino porque Elimina las CSC ""…

RT @pharma_jonpi: Zepsyre ... Otras Dos Expectativa Más . "" Es Altamente Efectivo en el Cáncer Cervical Uterino porque Elimina las CSC ""…

RT @pharma_jonpi: Zepsyre ... Otras Dos Expectativa Más . "" Es Altamente Efectivo en el Cáncer Cervical Uterino porque Elimina las CSC ""…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 6 additional X posts.